A new drug targeting Ly6E for advanced solid tumors
Part of Cancer, Digestive system, Hormones & metabolism, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new drug called M7437 that targets a protein (Ly6E) found on some cancer cells. It is for people with advanced solid tumors that have not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have one of these cancers: non-small cell lung cancer, triple-negative breast cancer, head and neck cancer, pancreatic cancer, stomach cancer, or ovarian cancer.
- Your cancer has spread or cannot be removed, and standard treatments have either stopped working or are not available for you.
- You are able to do light daily activities (like walking or light housework).
- Your blood cell counts, liver, and kidney function are within safe levels.
- You do not have brain metastases that are not treated or stable, severe diarrhea, or active bowel problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug that targets a protein called MET found on some cancer cells. It may help people with certain advanced cancers that have not responded to other treatments.
This trial tests a new drug called CKD-703 for people with advanced solid tumors, including a type of lung cancer (non-small cell lung cancer) that has a specific marker called c-Met. The study aims to see if the drug is safe and effective for those who have already tried other treatments that didn't work or caused side effects.
This trial tests a new investigational drug, BMS-986488, alone or with another drug (adagrasib), for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and works against certain cancers.
This trial is testing whether a new drug called CT7439 can help people with advanced solid tumors that have not responded to other treatments. It is a phase 1/2 study that also checks the drug's safety and how well it works.
This trial tests a new targeted drug (LY4175408) for people with certain advanced solid tumors (lung, endometrial, or triple negative breast cancer) who have already tried standard treatments. The goal is to see if the drug is safe and effective.
This trial tests a new medication for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.